2018
Genomics of Peritoneal Malignancies
Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surgical Oncology Clinics Of North America 2018, 27: 463-475. PMID: 29935683, DOI: 10.1016/j.soc.2018.02.004.Peer-Reviewed Original ResearchConceptsPeritoneal malignancyPeritoneal metastasisSimilar genetic mutationsEpithelial-mesenchymal transitionBiologic therapySurgical resectionMetastatic lesionsPredictive markerPrimary tumorIntraabdominal organsAggressive cancerMultiple cancersMetastasisMalignancyGenetic mutationsCancerOrgansResectionChemotherapyPeritoneumTherapyLesionsTumorsAbdomenAdjunctExtraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care
Lynch AD, Gani F, Meyer CF, Morris CD, Ahuja N, Johnston FM. Extraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care. Surgical Oncology 2018, 27: 373-379. PMID: 30217290, DOI: 10.1016/j.suronc.2018.05.016.Peer-Reviewed Original ResearchConceptsExtraskeletal Ewing's sarcomaCharlson-Deyo scoreOverall survivalTriple therapyCombination therapyLocal therapyEwing's sarcomaProportional hazards regression analysisHazards regression analysisSkeletal Ewing sarcomaEwing's sarcoma patientsAdult patientsIndependent predictorsEE patientsSarcoma patientsRisk factorsTreatment characteristicsSmall tumorsOutcome differencesPatientsTherapyAdult populationLack of consensusChemotherapyRegression analysis
2017
Genomics of peritoneal surface malignancies
Singh J, Sharma A, Ahuja N. Genomics of peritoneal surface malignancies. Journal Of Peritoneum (and Other Serosal Surfaces) 2017, 2 DOI: 10.4081/joper.2017.62.Peer-Reviewed Original ResearchPeritoneal malignancyHyperthermic intraperitoneal chemotherapyPeritoneal surface malignanciesLong-term survivalPrediction of responseAppendiceal neoplasmsIntraperitoneal chemotherapySurface malignanciesPeritoneal mesotheliomaPeritoneal metastasisPseudomyxoma peritoneiAggressive cytoreductionColorectal cancerTargeted therapyTerminal diseaseTherapeutic markersClinical decisionMalignancyClinical therapyTherapyGenomic alterationsMetastasisGenomic anomaliesGenomic characterizationCytoreductionInhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
Siebenkäs C, Chiappinelli KB, Guzzetta AA, Sharma A, Jeschke J, Vatapalli R, Baylin SB, Ahuja N. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLOS ONE 2017, 12: e0179501. PMID: 28622390, PMCID: PMC5473589, DOI: 10.1371/journal.pone.0179501.Peer-Reviewed Original ResearchConceptsSubset of patientsOvarian cancer cell linesAntigen processingCancer cell linesImmune therapyCancer testisSolid tumorsCell linesCancer cellsCancer-testis antigensHost immune systemOvarian cancer cellsTreatment time pointsEpigenetic therapyRelevant low dosesPresentation machineryImmune cellsOvarian cancerAntigen presentationMurine modelTestis antigensInnovative therapiesImmune systemLow dosesTherapyEpigenetic therapy and chemosensitization in solid malignancy
Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treatment Reviews 2017, 55: 200-208. PMID: 28431263, DOI: 10.1016/j.ctrv.2017.03.008.Peer-Reviewed Original ResearchConceptsCombination therapyEpigenetic therapySpecific hematologic malignanciesCertain solid tumorsHistone deacetylase inhibitorsDurable responsesSystemic therapyPatient subsetsSolid malignanciesHematologic malignanciesOvarian cancerBreast cancerDNA methyltransferase inhibitorEpigenetic changesSolid tumorsDeacetylase inhibitorsStandard chemotherapeuticsTherapyClinical potentialCancer cellsTrialsNSCLCMalignancyMethyltransferase inhibitorHypermethylation patterns
2015
Personalized Approaches to Gastrointestinal Cancers Importance of Integrating Genomic Information to Guide Therapy
He J, Ahuja N. Personalized Approaches to Gastrointestinal Cancers Importance of Integrating Genomic Information to Guide Therapy. Surgical Clinics Of North America 2015, 95: 1081-1094. PMID: 26315525, DOI: 10.1016/j.suc.2015.05.002.Peer-Reviewed Original ResearchConceptsGenetic testingPersonalized approachHigh-risk family membersCancer prevention strategiesComplex tumor heterogeneityTherapeutic decision makingProphylactic surgeryClinical trialsPrevention strategiesCancer behaviorGermline mutationsSuch personalized approachesTumor heterogeneityPatientsTherapyFamily membersBiopsySurgeryCancerCliniciansDifferent groupsTrialsA randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
Reiss K, Ahuja N, Baylin S, Mauro L, Linden S, White S, Laheru D, Herman J, Wolfgang C, Weiss M, Cameron J, Makary M, Azad N. A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. Journal Of Clinical Oncology 2015, 33: tps4144-tps4144. DOI: 10.1200/jco.2015.33.15_suppl.tps4144.Peer-Reviewed Original Research
2014
High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program
Moningi S, Armour EP, Terezakis SA, Efron JE, Gearhart SL, Bivalacqua TJ, Kumar R, Le Y, Ng S, Wolfgang CL, Zellars RC, Ellsworth SG, Ahuja N, Herman JM. High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program. Journal Of Contemporary Brachytherapy 2014, 6: 99-105. PMID: 24790628, PMCID: PMC4003434, DOI: 10.5114/jcb.2014.42027.Peer-Reviewed Original ResearchRate intraoperative radiation therapyIntraoperative radiation therapyRadiation therapyLocal controlGroup of patientsEffective local controlPelvic solid tumorsHDR-IORTRecurrent tumorsTrue efficacySolid tumorsMultidisciplinary approachPatientsTherapyTumorsIORT programProper administrationIORTSpecialized institutionsMalignancyOncologistsAnesthesiologistsPhysics staffNursesSurgeonsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5: 587-598. PMID: 24583822, PMCID: PMC3996658, DOI: 10.18632/oncotarget.1782.Peer-Reviewed Original ResearchConceptsDNA methyltransferase inhibitorImmune gene setsImmune-stimulatory roleCytokines/chemokinesCancer-testis antigensGene expression subsetsMethyltransferase inhibitorEpigenetic therapyHuman epithelial cancersMechanism of actionCancer cell linesPrimary tumorGene Set Enrichment AnalysisImmunomodulatory pathwaysImmune regulationPotential therapyTestis antigensPatient biopsiesSolid tumorsEpithelial cancersMultiple cancersLow dosesTumor expression dataAntigen processingTherapy
2008
Management of Extremity Soft Tissue Sarcomas
Hueman MT, Thornton K, Herman JM, Ahuja N. Management of Extremity Soft Tissue Sarcomas. Surgical Clinics Of North America 2008, 88: 539-557. PMID: 18514697, DOI: 10.1016/j.suc.2008.04.003.Peer-Reviewed Original ResearchManagement of Retroperitoneal Sarcomas
Hueman MT, Herman JM, Ahuja N. Management of Retroperitoneal Sarcomas. Surgical Clinics Of North America 2008, 88: 583-597. PMID: 18514700, DOI: 10.1016/j.suc.2008.03.002.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaLocal recurrenceMorbidity of therapyDistant metastatic diseaseAggressive surgical approachCurative treatment optionManagement of patientsHigh-grade lesionsMetastatic diseaseSurgical therapyTherapeutic challengeSurgical approachTreatment optionsExtent of invasionDisease controlSarcomaCommon typePatientsRecurrenceTherapyMorbidityLesionsManagementDiseaseDiagnosis